ODC1, ornithine decarboxylase 1, 4953

N. diseases: 184; N. variants: 2
Disease: Childhood Neuroblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment. 30700572 2019
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE The DHPS inhibitor GC7 (<i>N</i><sup>1</sup>-guanyl-1,7-diaminoheptane) and the ODC inhibitor α-difluoromethylornithine (DFMO) are target-specific and in combination induced synergistic effects in NB at concentrations that were not individually cytotoxic. 29295892 2018
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase with minimal single-agent clinical response data) is being used for maintenance therapy of neuroblastoma. 30251395 2018
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE To this end, the MYC-ODC axis presents an attractive target for managing cancers such as neuroblastoma, a pediatric malignancy in which <i>MYCN</i> gene amplification correlates with poor prognosis and high-risk disease. 30404920 2018
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase) is reported to modulate polyamines to potentially attenuate proliferation of neuroblastoma cells. 29626790 2018
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE By this study, a regulatory loop is proposed, wherein, ODC silencing in Y79 cells to result in decreased polyamine levels, thereby, leading to altered protein levels of Lin28b, MMP-2 and MMP-9, which falls in line with earlier studies in neuroblastoma. 29241071 2018
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes <i>ODC1</i> and <i>E2F2</i> DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. 28209620 2017
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC Neuroblastoma is a lethal tumor in which the MYC homologue MYCN, and ODC1, the rate-limiting enzyme in polyamine synthesis, are frequently deregulated so we tested optimized polyamine depletion regimens for activity against neuroblastoma. 27012811 2016
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE This study investigated safety, response, pharmacokinetics, genetic and metabolic factors associated with ODC in a clinical trial of the ODC inhibitor difluoromethylornithine (DFMO) ± etoposide for patients with relapsed or refractory NB. 26018967 2015
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE We earlier presented evidence for a physical interaction between ODC and SPR and we showed that RNAi-mediated knockdown of SPR expression significantly reduced native ODC enzyme activity and impeded NB cell proliferation. 26093909 2015
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Difluoromethylornithine (DFMO) is an inhibitor of ODC in clinical trials for children with NB. 25415050 2015
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Inhibiting ODC in NB cells produces many deleterious effects including G(1) cell cycle arrest, inhibition of cell proliferation, and decreased tumor growth, making ODC a promising target for drug interference. 23440295 2013
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE ODC mRNA expression in NB tumors was significantly predictive of decreased overall survival probability and correlated with several unfavorable clinical NB characteristics (all p < 0.005). 19960435 2010
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. 19147568 2009
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Indeed, elevated ODC1 (independent of MYCN amplification) was associated with reduced survival in a large independent neuroblastoma cohort. 19047152 2008
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 GeneticVariation disease BEFREE Finally, we describe the development and validation of a functional MYCN reporter gene assay using neuroblastoma cells (NGP) which have been stably transfected with a luciferase gene construct under control of the ornithine decarboxylase gene promoter. 12880971 2003
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE The R6ODC regulatory sequence was approximately equivalent to the CMV promoter in inducing expression of the neomycin resistance gene in c-MYC-expressing SW480 and HT-29 colon carcinoma cells and in N-MYC-expressing NB-1691 neuroblastoma cells. 11306486 2001
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11. 10933967 2000
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. 8761302 1996
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group. 8622876 1996
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 AlteredExpression disease BEFREE We have previously shown that asparagine alone induces a 10-15-fold increase in ornithine decarboxylase (ODC) mRNA level in DF-40 mouse neuroblastoma cells. 7954361 1994
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE We report here that genomic DNA from 1 of 6 primary neuroblastoma tumors containing amplified N-myc also contains amplified sequences homologous to a hamster ODC cDNA. 2780050 1989
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE A human neuroblastoma cell line with an altered ornithine decarboxylase. 6436232 1984